- Home
- KPTI vs NYC Comparison
KPTI vs NYC Comparison
Compare KPTI & NYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- NYC
- Stock Information
- Founded
- KPTI 2008
- NYC 2013
- Country
- KPTI United States
- NYC United States
- Employees
- KPTI N/A
- NYC N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- NYC Real Estate
- Sector
- KPTI Health Care
- NYC Finance
- Exchange
- KPTI Nasdaq
- NYC Nasdaq
- Market Cap
- KPTI 33.6M
- NYC 27.6M
- IPO Year
- KPTI 2013
- NYC N/A
- Fundamental
- Price
- KPTI $4.21
- NYC $12.43
- Analyst Decision
- KPTI Strong Buy
- NYC
- Analyst Count
- KPTI 5
- NYC 0
- Target Price
- KPTI $61.00
- NYC N/A
- AVG Volume (30 Days)
- KPTI 172.5K
- NYC 6.9K
- Earning Date
- KPTI 05-07-2025
- NYC 05-09-2025
- Dividend Yield
- KPTI N/A
- NYC N/A
- EPS Growth
- KPTI N/A
- NYC N/A
- EPS
- KPTI N/A
- NYC N/A
- Revenue
- KPTI $145,237,000.00
- NYC $61,570,000.00
- Revenue This Year
- KPTI $4.87
- NYC $8.40
- Revenue Next Year
- KPTI $16.29
- NYC $1.62
- P/E Ratio
- KPTI N/A
- NYC N/A
- Revenue Growth
- KPTI N/A
- NYC N/A
- 52 Week Low
- KPTI $3.51
- NYC $5.46
- 52 Week High
- KPTI $21.30
- NYC $12.52
- Technical
- Relative Strength Index (RSI)
- KPTI 37.33
- NYC 67.66
- Support Level
- KPTI $3.83
- NYC $11.10
- Resistance Level
- KPTI $4.36
- NYC $11.95
- Average True Range (ATR)
- KPTI 0.55
- NYC 1.15
- MACD
- KPTI 0.13
- NYC 0.14
- Stochastic Oscillator
- KPTI 25.64
- NYC 98.36
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.